BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 28414296)

  • 1. PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells.
    Ni X; Song Q; Cassady K; Deng R; Jin H; Zhang M; Dong H; Forman S; Martin PJ; Chen YZ; Wang J; Zeng D
    J Clin Invest; 2017 May; 127(5):1960-1977. PubMed ID: 28414296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 serves as a double agent in separating GVL from GVHD.
    Brennan TV; Yang Y
    J Clin Invest; 2017 May; 127(5):1627-1630. PubMed ID: 28414300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80.
    Cassady K; Martin PJ; Zeng D
    Front Immunol; 2018; 9():3061. PubMed ID: 30622541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells.
    Koestner W; Hapke M; Herbst J; Klein C; Welte K; Fruehauf J; Flatley A; Vignali DA; Hardtke-Wolenski M; Jaeckel E; Blazar BR; Sauer MG
    Blood; 2011 Jan; 117(3):1030-41. PubMed ID: 21063028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Donor T cell STAT3 deficiency enables tissue PD-L1-dependent prevention of graft-versus-host disease while preserving graft-versus-leukemia activity.
    Li Q; Wang X; Song Q; Yang S; Wu X; Yang D; Marié IJ; Qin H; Zheng M; Nasri U; Kong X; Wang B; Lizhar E; Cassady K; Tompkins J; Levy D; Martin PJ; Zhang X; Zeng D
    J Clin Invest; 2023 Aug; 133(15):. PubMed ID: 37526084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerogenic anti-IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity.
    Song Q; Wang X; Wu X; Qin H; Li Y; Riggs AD; Martin PJ; Chen YZ; Zeng D
    Blood; 2021 Apr; 137(16):2243-2255. PubMed ID: 33511398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells.
    Yang YG; Qi J; Wang MG; Sykes M
    Blood; 2002 Jun; 99(11):4207-15. PubMed ID: 12010827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.
    Deng R; Cassady K; Li X; Yao S; Zhang M; Racine J; Lin J; Chen L; Zeng D
    J Immunol; 2015 Jan; 194(2):560-74. PubMed ID: 25488990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes.
    Okiyama N; Katz SI
    J Autoimmun; 2014 Sep; 53():1-9. PubMed ID: 25047812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. During acute graft versus host disease CD28 deletion in donor CD8
    Uri A; Lühder F; Kerkau T; Beyersdorf N
    Eur J Immunol; 2018 Dec; 48(12):2055-2067. PubMed ID: 30320878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice.
    Wu Y; Heinrichs J; Bastian D; Fu J; Nguyen H; Schutt S; Liu Y; Jin J; Liu C; Li QJ; Xia C; Yu XZ
    Blood; 2015 Sep; 126(11):1314-23. PubMed ID: 26138686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity.
    Song Q; Nasri U; Nakamura R; Martin PJ; Zeng D
    Front Immunol; 2022; 13():907673. PubMed ID: 35677056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.
    Saha A; O'Connor RS; Thangavelu G; Lovitch SB; Dandamudi DB; Wilson CB; Vincent BG; Tkachev V; Pawlicki JM; Furlan SN; Kean LS; Aoyama K; Taylor PA; Panoskaltsis-Mortari A; Foncea R; Ranganathan P; Devine SM; Burrill JS; Guo L; Sacristan C; Snyder NW; Blair IA; Milone MC; Dustin ML; Riley JL; Bernlohr DA; Murphy WJ; Fife BT; Munn DH; Miller JS; Serody JS; Freeman GJ; Sharpe AH; Turka LA; Blazar BR
    J Clin Invest; 2016 Jul; 126(7):2642-60. PubMed ID: 27294527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL.
    Matte-Martone C; Liu J; Jain D; McNiff J; Shlomchik WD
    Blood; 2008 Apr; 111(7):3884-92. PubMed ID: 18223170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease.
    Juchem KW; Sacirbegovic F; Zhang C; Sharpe AH; Russell K; McNiff JM; Demetris AJ; Shlomchik MJ; Shlomchik WD
    J Immunol; 2018 Jan; 200(2):834-846. PubMed ID: 29212909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ.
    Anderson BE; McNiff JM; Jain D; Blazar BR; Shlomchik WD; Shlomchik MJ
    Blood; 2005 Mar; 105(5):2227-34. PubMed ID: 15522961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infusion of anti-B7.1 (CD80) and anti-B7.2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells.
    Blazar BR; Sharpe AH; Taylor PA; Panoskaltsis-Mortari A; Gray GS; Korngold R; Vallera DA
    J Immunol; 1996 Oct; 157(8):3250-9. PubMed ID: 8871619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.